Applicants: Ilya Trakht et al.

Serial No.: 09/664,958

Filed: September 18, 2000

Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

Claims 1-5. (Cancelled)

Claim 6. (Currently amended): A monoclonal antibody which specifically binds and forms a complex with TIP-2 antigen located on the surface of human cancer cells expressing TIP-2, wherein the monoclonal antibody binds to the same extracellular domain of extracellularly to TIP-2 as does monoclonal antibody 27.Bl produced by hybridoma 27.Bl (ATCC Designation No. PTA-1599).

Claim 7. (Original): The monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599).

Claim 8. (Cancelled)

Claim 9. (Previously presented): The hybridoma cell designated 27.Bl (ATCC Accession No. PTA-1599).

Claims 10-15. (Cancelled)

Claim 16. (Currently amended): A monoclonal antibody which specifically binds and forms a complex with TIP-2 antigen located on the surface of fixed human cancer cells expressing TIP-2, wherein the monoclonal antibody binds to the same

Applicants:

Ilya Trakht et al.

Serial No.:

09/664,958

Filed: Page 3

September 18, 2000

extracellular domain of intracellularly to TIP-2 as does monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).

- Claim 17. (Original): The monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. 1598).
- Claim 18. (Previously presented): The hybridoma cell designated 27.F7 (ATCC Accession No. PTA-1598).

Claims 19-174. (Cancelled)

- Claim 175. (Currently amended): A kit for detecting the presence of TIP-2 antigen-bearing cancer cells in a sample comprising:
 - a) a solid support having a plurality of immobilized probes which may be the same or different, wherein each probe comprises a monoclonal antibody or Fab fragment thereof which specifically binds and forms a complex with TIP-2 antigen located on the surface of human cancer cells; and
 - b) a means for determining the presence of the probe/TIP-2 antigen complex.
- Claim 176. (Currently amended): The kit of claim 175, wherein the probe binds extracellularly to the same TIP-2 domain as does monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599) or intracellularly to TIP-2 on fixed cells as does monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).

Applicants: I

Ilya Trakht et al.

Serial No.: 09/664,958

Filed: Page 4

September 18, 2000

Claim 177. (Previously presented): The kit of claim 176, wherein the probe is a murine monoclonal antibody.

- Claim 178. (Previously presented): The kit of claim 176, wherein the probe is a chimeric monoclonal antibody.
- Claim 179. (Previously presented): The kit of claim 176, wherein the probe is a humanized monoclonal antibody.
- Claim 180. (Previously presented): The kit of claim 176, wherein the probe is a human monoclonal antibody.
- Claim 181. (Previously presented): The kit of claim 176, wherein the probe is human monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599) or human monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).
- Claim 182. (Currently amended): The kit of claim 176, wherein the means for determining the presence of the probe/TIP-2 antigen complex comprises a detectably labeled antibody.
- Claim 183. (Currently amended): The kit of claim 176, wherein the means for determining the presence of the probe/TIP-2 antigen complex comprises a detectably labeled antibody which specifically binds to a monoclonal antibody directed to TIP-2 antigen.

Applicants:

Ilya Trakht et al.

Serial No.:

09/664,958

Filed: Page 5

September 18, 2000

Claim 184.

(Previously presented): The kit of claim 182 or 183, wherein the detectable label is a radioactive isotope, enzyme, dye, biotin, fluorescent label or chemiluminescent label.